How to buy Q BioMed Inc (QBIO) stock when it goes public

Q BioMed Inc stock is not yet available to purchase on any exchange. But it's expected to go public soon. Here's what we know — and how to buy in when it launches.

What we know about the Q BioMed Inc IPO

Q BioMed Inc filed a draft registration with the US Securities and Exchange Commission under the ticker symbol QBIO. Not yet an official IPO, it's one of the first steps of taking a private company public.

There's no news yet about how much the stock will cost when it goes public. No date has been set for when the stock will be publicly available. The shares will be available on the Nasdaq Capital Market.

How to buy shares in Q BioMed Inc when it goes public

Once Q BioMed Inc goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Q BioMed Inc. Find the stock by name or ticker symbol: QBIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy immediately with a market order or use a limit order to delay your purchase until Q BioMed Inc reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Q BioMed Inc, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Q BioMed Inc. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Beginners

Robinhood

Our top pick for

Casual investors

Interactive Brokers

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like Q BioMed Inc can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.

• CNS Pharmaceuticals (CNSP.US)

  Company summary

  CNS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.

  Historical performance

  Stock information

  • Market capitalization: $45803904
  • P/E ratio: -99999.99
  • Dividend yield: N/A%

  Get more detailed information and learn how to buy CNSP.US stock

• Moleculin Biotech (MBRX.US)

  Company summary

  Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

  Historical performance

  Stock information

  • Market capitalization: $60590664
  • PEG ratio: 0
  • Dividend yield: 0%

  Get more detailed information and learn how to buy MBRX.US stock

• Pliant Therapeutics (PLRX.US)

  Company summary

  Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

  Historical performance

  Stock information

  • Market capitalization: $927089728
  • P/E ratio: 42.7543
  • Dividend yield: N/A%

  Get more detailed information and learn how to buy PLRX.US stock

Compare trading platforms

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee
Sofi Invest		$0	Stocks, ETFs, Cryptocurrency	N/A	0%	A free way to invest in stocks, ETFs and crypto.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Forex	$0 + $0.65/contract, $1 minimum	0%	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Public		$0	Stocks, ETFs	N/A		Go to site More Info		loading Fetching your data...
Robinhood		$0	Stocks, Options, ETFs, Cryptocurrency	$0	0%	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Titan		$0	Stocks, Bonds	N/A	1%	Go to site		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare